AVITA Medical, Inc.(RCEL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,745 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
RCEL Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for AVITA Medical, Inc. (RCEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCEL at 22.8/100 on a 32-signal composite quality model, placing it at rank #2,745 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.3) and earnings quality (1.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), AVITA Medical, Inc. reports quarterly revenue of $21.7M, net income of $-7.7M, free cash flow of $-3.6M. Top institutional holders of RCEL by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. RCEL trades on the Nasdaq exchange and files with the SEC under CIK 1762303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVITA Medical, Inc. directly from SEC EDGAR. AVITA Medical, Inc.'s 13F Pro composite quality score has ranged between 23 and 28 since 2021, currently 22.8 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.
Revenue
Q2 2026
$21.7M
Net Income
Q2 2026
$-7.7M
Free Cash Flow
Q2 2026
$-3.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
Operating Income
EPS (Diluted)
Total Assets
-17.8% YoYTotal Debt
+10.5% YoYOp. Cash Flow
Free Cash Flow
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $29.2M |
| Net Income | — | — | — | — | — | $-26.6M |
| Operating Income | — | — | — | — | — | $-26.5M |
| EPS (Diluted) | — | — | — | — | — | $1.17 |
| Total Assets | $47.8M -17.8% | $58.1M -33.8% | $87.8M +1.7% | $86.3M -15.9% | $102.7M -18.2% | $125.5M |
| Total Debt | $46.7M +10.5% | $42.2M +3.0% | $41.0M | — | — | — |
| Operating Cash Flow | — | — | — | — | — | $-25.9M |
| Free Cash Flow | — | — | — | — | — | $-26.8M |
Get alerted when RCEL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AVITA Medical, Inc. including:
Top Institutional Holders of RCEL
VANGUARD CAPITAL MANAGEMENT LLC
$5.5M1,333,914 shBlackRock, Inc.
$2.3M564,952 shGEODE CAPITAL MANAGEMENT, LLC
$1.4M339,822 shMARSHALL WACE, LLP
$1.4M338,387 shAQR CAPITAL MANAGEMENT LLC
$1.3M321,013 shMORGAN STANLEY
$827.9K200,462 shVANGUARD FIDUCIARY TRUST CO
$753.3K182,402 shNewEdge Advisors, LLC
$615.1K148,931 shMACQUARIE GROUP LTD
$595.4K144,164 shSTATE STREET CORP
$532.7K128,977 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.5M | 1,333,914 |
| BlackRock, Inc. | $2.3M | 564,952 |
| GEODE CAPITAL MANAGEMENT, LLC | $1.4M | 339,822 |
| MARSHALL WACE, LLP | $1.4M | 338,387 |
| AQR CAPITAL MANAGEMENT LLC | $1.3M | 321,013 |
| MORGAN STANLEY | $827.9K | 200,462 |
| VANGUARD FIDUCIARY TRUST CO | $753.3K | 182,402 |
| NewEdge Advisors, LLC | $615.1K | 148,931 |
| MACQUARIE GROUP LTD | $595.4K | 144,164 |
| STATE STREET CORP | $532.7K | 128,977 |
More Healthcare Companies
View all Healthcare →Put RCEL on your watchlist
Track score changes the day AVITA Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RCEL a good stock to buy?
13F Pro's AI-powered analysis of AVITA Medical, Inc. (RCEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RCEL are available on the RCEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RCEL is classified as a small company.
Which hedge funds own RCEL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RCEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AVITA Medical, Inc.'s investment landscape.